Eric Daniels
Corporate Officer/Principal bei KIORA PHARMACEUTICALS, INC.
Vermögen: 42 288 $ am 30.04.2024
Profil
Eric J.
Daniels is the founder of Okogen, Inc., Bayon Therapeutics, Inc. He is currently the Chief Development Officer at Kiora Pharmaceuticals, Inc. His former position was as the Chief Executive Officer at OccuRx Pty Ltd.
Dr. Daniels has an undergraduate degree from the University of California, Berkeley, a doctorate from the David Geffen School of Medicine, and an MBA from the Anderson School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.03.2024 | 88 100 ( 0,34% ) | 42 288 $ | 30.04.2024 |
Aktive Positionen von Eric Daniels
| Unternehmen | Position | Beginn |
|---|---|---|
| KIORA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 21.10.2021 |
Okogen, Inc.
 Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Gründer | - |
| Bayon Therapeutics, Inc. | Gründer | - |
Ehemalige bekannte Positionen von Eric Daniels
| Unternehmen | Position | Ende |
|---|---|---|
OccuRx Pty Ltd
 OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia. | Vorstandsvorsitzender | - |
Ausbildung von Eric Daniels
| University of California, Berkeley | Undergraduate Degree |
| David Geffen School of Medicine | Doctorate Degree |
| Anderson School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KIORA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Okogen, Inc.
Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Commercial Services |
OccuRx Pty Ltd
OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia. | Health Technology |
| Bayon Therapeutics, Inc. |
